In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epirus Biopharmaceuticals Inc.

www.epirusbiopharma.com

Latest From Epirus Biopharmaceuticals Inc.

Another Infliximab Biosimilar On Horizon In India?

More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.

Policy & Regulation Biosimilars

Appointments: Piramal Pharma, Oxeia, Artios Eyevensys and Bone Therapeutics

This week's roundup includes a new CEO for Oxeia, in addition to various other high-level appointments by Piramal Pharma Solutions, Bone Therapeutics, Kiadis and biOasis. Artios Pharma also welcomes AstraZeneca's former senior director bioscience, oncology to its team.

Appointments BioPharmaceutical

Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target

Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.

Biosimilars Rare Diseases

Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target

Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.

Biosimilars Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • fourteen22 Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Epirus Biopharmaceuticals Inc.
  • Senior Management
  • Amit Munshi, Pres. & CEO
    Tom Shea, CFO
    Nick Plumeridge, SVP, Global Bus. Dev. & Licensing
    Cheryl Lassen, MD, VP, Clinical Dev.
    Alex Waldron, VP, Global Commercial Operations
  • Contact Info
  • Epirus Biopharmaceuticals Inc.
    Phone: (617) 600-3497
    699 Boylston St., 8th Fl.
    11th Floor
    , MA 02116
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register